Tiziana Life Sciences Ltd (TLSA)

0.7450 +0.0360 (+5.08%) 收市：04:00PM EDT

Tiziana Life Sciences Ltd

14/15 Conduit Street
London W1S 2XJ
United Kingdom

https://www.tizianalifesciences.com

版塊: Healthcare
行業: Biotechnology
全職員工: 9

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Gabriele Marco Antonio Cerrone M.B.A.	Founder, Executive Chairman & Interim CEO	444k	無	1972
Dr. Andrea Brancale	Scientific Founder	無	無	無
Mr. Richard Clarkson Ph.D.	Scientific Founder	無	無	無
Mr. Andrew Westwell Ph.D.	Scientific Founder	無	無	無
Ms. Keeren Shah	Chief Financial Officer	無	無	1976
Dr. Matthew W. Davis M.D., R.Ph.	COO & Chief Medical Officer	無	無	無
Dr. William A. Clementi Ph.D., Pharm.D.	Chief Development Officer	無	無	無
Dr. Napoleone Ferrara M.D.	Member of Scientific Advisory Board	無	無	1958

截止 2022年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.

公司管治

截至 無 止，Tiziana Life Sciences Ltd 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。